Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Innovent Reports Trial Data from PD-1 Drug in Three Separate Indications

publication date: Jun 3, 2020

At the virtual ASCO conference, Suzhou Innovent announced clinical results from three trials of its PD-1 drug, Tyvyt®:

• In a Phase II trial among patients with relapsed or refractory classic Hodgkin's lymphoma, the ORR was 85.4% and complete response (CR) 42.7%;
• In a two-year study among patients with relapsed or refractory extranodal NK/T-cell lymphoma, the ORR was 67.9% and the CR 14.3%;
• As a second-line treatment in patients with esophageal squamous cell carcinoma, the 12-month survival rates were 37.4% in the Tyvyt cohort and 21.4% in the chemotherapy group.

In 2018, Tyvyt was approved for use in China as a third-line treatment for patients with classical Hodgkin's lymphoma. It is currently being tested in 20 clinical trials. More details....

Stock Symbol: (HK: 01801)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital